EU lays out pros and cons to on­shoring more API pro­duc­tion

As the US em­barks on a bil­lion-dol­lar ini­tia­tive to on­shore ac­tive phar­ma­ceu­ti­cal in­gre­di­ent (API) man­u­fac­tur­ing, the Eu­ro­pean Union re­leased a re­port ear­li­er this month weigh­ing the pros and cons of any pos­si­ble reshoring of API pro­duc­tion.

The 58-page re­port notes that over the past decade, med­i­cine short­ages have been in­creas­ing through­out Eu­rope, as they have across the pond, with con­cerns raised that out­sourc­ing API man­u­fac­tur­ing abroad may have con­tributed to dis­rup­tions in the sup­ply chain. A pro­pos­al to reshore API man­u­fac­tur­ing to EU mem­ber states has been pro­posed, but it’s un­clear if it will gain trac­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER